| |
Madrid |
Andalusia |
Overall |
| n=229 |
n=324 |
n=553 |
| Age, years |
|
|
|
| Mean (SD) |
4.2 (0.20) |
5.9 (0.29) |
5.2 (0.89) |
| Gender, (n (%))[1] |
|
|
|
| Male |
103 (45.0) |
161 (49.7) |
264 (47.7) |
| Female |
126 (55.0) |
163 (50.3) |
289 (52.3) |
| Concomitant vaccination, (n (%))a |
227 (99.1) |
4 (1.2) |
231 (41.8) |
| Haemophilusinfluenzae type b vaccines |
1 (0.4) |
0 (0.0) |
1 (0.4) |
| Measles vaccines |
226 (98.7) |
1 (25.0) |
227 (97.4) |
| Meningococcal vaccines |
0 (0.0) |
1 (25.0) |
1 (0.4) |
| Pneumococcal vaccines |
1 (0.4) |
0 (0.0) |
1 (0.4) |
| Poliomyelitis vaccines |
1 (0.4) |
0 (0.0) |
1 (0.4) |
| Varicella Zoster vaccines |
0 (0) |
2 (50.0) |
2 (0.9) |
| Disease on day of inclusion, (n (%))a |
|
|
|
| Acute disease |
6 (2.6) |
14 (4.3) |
20 (3.6) |
| Chronic disease |
24 (10.5) |
32 (9.9) |
56 (10.1) |
| Medication prior to inclusion[2], (n (%))a |
11 (4.8) |
5 (1.5) |
16 (2.9) |
| Concomitant medication, (n (%))a |
23 (10.0) |
33 (10.2) |
56 (10.1) |
| Medication used to treat ARs, (n (%))a |
36 (7.0) |
89 (13.5) |
125 (10.6) |
| Medication used to treat ARs, (n (%))[3] |
|
|
|
| Antibiotics for topical use |
0 (0.0) |
2 (3.2) |
2 (2.1) |
| Antihistamines for systemic use |
1 (2.9) |
1 (1.6) |
2 (2.1) |
| Antiinflammatory and antirheumatic products, NSAIDs |
21 (61.8) |
51 (82.3) |
72 (75.0) |
| Antivaricose therapy |
0 (0.0) |
1 (1.6) |
1 (1.0) |
| Corticosteroids for systemic use |
0 (0.0) |
2 (3.2) |
2 (2.1) |
| Corticosteroids |
1 (2.9) |
2 (3.2) |
3 (3.1) |
| Other analgesics and antipyretics |
10 (29.4) |
3 (4.8) |
13 (13.5) |
| Motility stimulants |
1 (2.9) |
0 (0.0) |
1 (1.0) |
